Kazakhstan
Key Insights
- 1
No psychedelic therapy is approved in Kazakhstan; patient access appears limited to standard hospital care, with esketamine not evidenced as a routine authorised option.
- 2
The database shows 1 trial, 0 active, 0 research organisations; esketamine and placebo are the only compounds recorded.
- 3
Kazakhstan’s standout milestone is scientific, not psychedelic: it launched the Soviet nuclear test site at Semipalatinsk in 1949, shaping later biomedical scrutiny.
- 4
Momentum is thin: with no active trials or organisations, any field lift would likely depend on new Ministry of Health approvals or foreign-sponsored study partnerships.
Reimbursed Care Access
Kazakhstan maintains a restrictive, control-focused approach to classical psychedelics and novel psychoactive compounds: most serotonergic psychedelics (psilocybin, MDMA, DMT, mescaline, 2C‑X, 5‑MeO‑DMT, ibogaine, ayahuasca) are listed in national controlled‑substance schedules with no authorized general medical use outside approved research. Ketamine is registered and used in medical practice (primarily anaesthesia and acute analgesia) and is subject to strengthened controls; esketamine (Spravato) does not appear to be registered for routine clinical psychiatric use in Kazakhstan as of available sources.
Quick Indicators
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Kazakhstan.